Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, Suni M, Maino VC, Henderson KE, Howbert JJ, Disis ML, Hershberg RM.

Clin Cancer Res. 2012 Jan 15;18(2):499-509. doi: 10.1158/1078-0432.CCR-11-1625.

2.

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.

Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM.

PLoS One. 2016 Feb 29;11(2):e0148764. doi: 10.1371/journal.pone.0148764.

3.

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.

Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL.

Cancer Immunol Immunother. 2013 Aug;62(8):1347-57. doi: 10.1007/s00262-013-1437-3.

4.

NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.

Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J, Briones J.

Exp Hematol. 2008 Jan;36(1):69-77.

PMID:
17959301
5.

The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.

Dowling DJ, Tan Z, Prokopowicz ZM, Palmer CD, Matthews MA, Dietsch GN, Hershberg RM, Levy O.

PLoS One. 2013;8(3):e58164. doi: 10.1371/journal.pone.0058164.

6.

TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.

Lu H, Yang Y, Gad E, Inatsuka C, Wenner CA, Disis ML, Standish LJ.

Clin Cancer Res. 2011 Nov 1;17(21):6742-53. doi: 10.1158/1078-0432.CCR-11-1142.

7.

Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.

Srivastava S, Pelloso D, Feng H, Voiles L, Lewis D, Haskova Z, Whitacre M, Trulli S, Chen YJ, Toso J, Jonak ZL, Chang HC, Robertson MJ.

Cancer Immunol Immunother. 2013 Jun;62(6):1073-82. doi: 10.1007/s00262-013-1403-0.

8.

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J.

Cancer Immunol Res. 2015 Oct;3(10):1148-57. doi: 10.1158/2326-6066.CIR-15-0059.

9.

[Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].

Qu YH, Li Y, Wu YF, Fang JP, Huang SL, Huang Y, Wei J.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Oct;18(5):1269-74. Chinese.

PMID:
21129274
10.

KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.

Terszowski G, Klein C, Stern M.

J Immunol. 2014 Jun 15;192(12):5618-24. doi: 10.4049/jimmunol.1400288.

11.

The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA.

Clin Cancer Res. 2016 Feb 1;22(3):596-608. doi: 10.1158/1078-0432.CCR-15-1419.

12.

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.

Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP.

Blood. 2007 Oct 1;110(7):2561-4.

14.

A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.

Vargas-Inchaustegui DA, Demberg T, Robert-Guroff M.

Immunology. 2011 Nov;134(3):326-40. doi: 10.1111/j.1365-2567.2011.03493.x.

15.

TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA.

Berger M, Ablasser A, Kim S, Bekeredjian-Ding I, Giese T, Endres S, Hornung V, Hartmann G.

J Immunother. 2009 Apr;32(3):262-71. doi: 10.1097/CJI.0b013e318198bd2a.

PMID:
19242374
16.
17.

TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.

Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM.

J Immunol. 2005 Aug 1;175(3):1636-42.

18.

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.

Hamm S, Rath S, Michel S, Baumgartner R.

J Immunotoxicol. 2009 Dec;6(4):257-65. doi: 10.3109/15476910903286733.

PMID:
19848448
19.

IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential.

Lehmann D, Spanholtz J, Sturtzel C, Tordoir M, Schlechta B, Groenewegen D, Hofer E.

PLoS One. 2014 Jan 31;9(1):e87131. doi: 10.1371/journal.pone.0087131.

20.

V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.

Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, Moriyasu F, Nieda M, Nicol AJ.

Int J Cancer. 2008 Jun 1;122(11):2526-34. doi: 10.1002/ijc.23365. Erratum in: Int J Cancer. 2011 Dec 1;129(11):2761. Fai-So, Hang [corrected to So, Hang-Fai].

Supplemental Content

Support Center